These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19081408)

  • 21. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
    Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention.
    Díez JG
    J Invasive Cardiol; 2008 Sep; 20(9):482-9. PubMed ID: 18762681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention.
    Montalescot G; Salette G; Steg G; Cohen M; White HD; Gallo R; Steinhubl SR
    Int J Cardiol; 2011 Jul; 150(1):79-83. PubMed ID: 20299114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
    Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
    Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions.
    Natarajan MK; Velianou JL; Turpie AG; Mehta SR; Raco D; Goodhart DM; Afzal R; Ginsberg JS
    Am Heart J; 2006 Jan; 151(1):175. PubMed ID: 16368313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of anticoagulants in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: a potential role for enoxaparin.
    Christy GW
    J Invasive Cardiol; 2008 Nov; 20(11):615-21. PubMed ID: 18987403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
    Cohen M; Levine GN; Pieper KS; Lan L; Antman EM; Aylward PE; White HD; Kleiman NS; Califf RM; Mahaffey KW;
    Catheter Cardiovasc Interv; 2010 May; 75(6):928-35. PubMed ID: 20432399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).
    Collet JP; Huber K; Cohen M; Zeymer U; Goldstein P; Pollack C; Silvain J; Henry P; Varenne O; Carrié D; Coste P; Angioi M; Le Breton H; Cayla G; Elhadad S; Teiger E; Filippi E; Aout M; Vicaut E; Montalescot G;
    Am J Cardiol; 2013 Nov; 112(9):1367-72. PubMed ID: 24012033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
    Montalescot G; Ellis SG; de Belder MA; Janssens L; Katz O; Pluta W; Ecollan P; Tendera M; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Armstrong P; Brodie BR; Herrmann HC; Neumann FJ; Effron MB; Lu J; Barnathan ES; Topol EJ;
    JACC Cardiovasc Interv; 2010 Feb; 3(2):203-12. PubMed ID: 20170878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
    Cohen M; Mahaffey KW; Pieper K; Pollack CV; Antman EM; Hoekstra J; Goodman SG; Langer A; Col JJ; White HD; Califf RM; Ferguson JJ;
    J Am Coll Cardiol; 2006 Oct; 48(7):1346-54. PubMed ID: 17010793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
    Cohen M; Bhatt DL; Alexander JH; Montalescot G; Bode C; Henry T; Tamby JF; Saaiman J; Simek S; De Swart J;
    Circulation; 2007 May; 115(20):2642-51. PubMed ID: 17502577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
    Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
    Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
    Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.
    Fox KA; Antman EM; Montalescot G; Agewall S; SomaRaju B; Verheugt FW; Lopez-Sendon J; Hod H; Murphy SA; Braunwald E
    J Am Coll Cardiol; 2007 Jun; 49(23):2249-55. PubMed ID: 17560289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weigh heparins in prevention of coronary micro-embolization].
    Dudek D; Zymek P; Bartuś S; Dubiel JS
    Przegl Lek; 2001; 58(6):484-6. PubMed ID: 11816736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.